Show Notes
The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD.
Related Content: Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments Pridopidine in Amyotrophic Lateral Sclerosis Platform Trials in ALS Verdiperstat in Amyotrophic Lateral Sclerosis Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis CNM-Au8 in Amyotrophic Lateral Sclerosis
More from Healthy Dialogue
Breast cancer has undergone a dramatic transformation over the past several decades. Five-year survival rates are now 92% compared with 76% in 1975. In this special 2-part episode of Healthy Dialogue, Nancy E. Davidson, MD, oncologist and chief academic officer and executive vice president of Fred Hutchinson Cancer Center, discusses the advancements that led to these improvements.
Approximately 1 in 5 Americans live in rural areas, and in the coming years they will see dramatic shifts in their health care options due to the One Big Beautiful Bill Act. In this episode of Healthy Dialogue Mark Holmes, PhD, joins host Derek C. Angus, MD, MPH, to explore the impact of upcoming cuts to Medicaid and the $50 billion Rural Health Transformation Program.
Long COVID is a debilitating condition impacting millions of people around the world, but is still poorly understood, poorly defined, and poorly treated. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, discusses long COVID with Wes Ely, MD, MPH, professor of medicine at Vanderbilt University, and co-author of the NASEM report on Long COVID.
Medicaid provides health insurance for 1 in 5 Americans and plays a crucial role in US health care infrastructure. The One Big Beautiful Bill Act (OBBBA) is estimated to cut Medicaid spending by nearly $1 trillion by 2034 and cause millions of enrollees to lose coverage. In this episode of Healthy Dialogue, Julie Donohue, PhD, professor and chair of health policy and management at the University of Pittsburgh, breaks down what Medicaid is, who it covers, and how proposed cuts in the OBBBA could have far-reaching effects on patients, clinicians, hospitals and communities.
GLP-1 receptor agonists are one of the most revolutionary new classes of drugs in decades. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, sat down with Jens Juul Holst, MD, DMSc, and Lotte Bjerre Knudsen, DMSc, 2 pioneering scientists behind the discovery and development of GLP-1 RAs. Together, they traced the fascinating origin story of GLP-1 RAs and offered their thoughts on what comes next.